A compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or control of a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD). In Formula I, E is sulphur (S) or selenium (Se). Preferably Formula I is either 2-phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen) or 2-phenyl-1,2-bezisothiazol-3(2H)-one (ebsulfur). Also claimed is a pharmaceutical composition comprising the compound of Formula I, a method of treating the impulsivity-related disorders listed above. In another embodiment is a kit comprising the compound of Formula I and one or more dopamine agonist, and the use of the compound of Formula I and one or more dopamine agonist in the treatment or control of an impulse control disorder in a patient who is also undergoing dopamine agonist treatment.
